Evaxion A/S shares jumped 8% after phase‑2 data showed its AI‑Immunology platform achieved an 86% success rate in identifying tumor‑specific vaccine targets.
The EVX‑01 vaccine combined with Merck’s Keytruda in advanced melanoma produced an 86% immune‑response rate, building on a prior 75% objective response over two years.
One‑year trial extension completed this month; three‑year data expected in the second half of 2026, with results to be presented at the AACR Annual Meeting on April 22, 2026.
Chief Scientific Officer Bigitte Rønø highlighted a positive correlation between AI prediction scores and the magnitude of immune responses.